The inflammatory response and IL1β overexpression were markedly improved by Propranolol, a β-blocker, by mitigating against epigenetic modifications thus suggesting that β-blockers have a therapeutic potential for IBD susceptibility, and establishing a novel paradigm whereby neonatal inflammation induces epigenetic susceptibility to IBD. The gene discussed is IL1B; the disease is inflammatory bowel disease.